Forebygging av hjerte- og karsykdom

Objectives

Norway’s national guideline for cardiovascular disease prevention supports primary and secondary prevention through risk assessment, lifestyle change, treatment of hypertension and lipid disorders, antiplatelet therapy where indicated, and structured follow-up. It sits within the 2013–2017 national strategy for non-communicable diseases, whose overarching objective was a 25% reduction in premature deaths from cardiovascular disease, diabetes, chronic obstructive pulmonary disease and cancer by 2025.[1][2]The guideline aims to provide updated, practical recommendations for assessment, treatment and counselling, including general secondary prevention for people with established coronary disease, peripheral atherosclerosis or ischaemic stroke.[2]

• Identify people at substantial cardiovascular risk using the NORRISK 2 10-year risk tool, while avoiding unnecessary long-term medication for people at very low risk.[3][4]
• Apply age-specific thresholds for preventive treatment, generally considering medicine after lifestyle measures when estimated 10-year risk remains at least 5% at ages 45–54, 10% at ages 55–64, and 15% at ages 65–74.[5][6]
• Assess treatment independently of calculated risk when risk factors are markedly elevated, including severe hypertension, high cholesterol, diabetes, familial hyperlipidaemia or cardiovascular end-organ damage.[5][7]
• Reduce modifiable risk through smoking cessation, healthier diet, physical activity, reduced sedentary behaviour, weight management and limiting alcohol intake.[8][9][10][11][12]
• Prevent recurrent cardiovascular events through secondary prevention, including antiplatelet treatment, lipid-lowering therapy, blood-pressure control, rehabilitation and tailored physical activity.[13][14][15][16]
• Tailor preventive decisions for older people, considering frailty, comorbidity, polypharmacy, life expectancy, treatment tolerance, quality of life and personal preferences.[17][18]

Implementation

The guideline is delivered principally through individualised clinical assessment and follow-up in primary care, supported by specialist referral where complexity, severe disease, suspected secondary causes or treatment resistance warrant it. General practitioners and other doctors, nurses, physiotherapists and authorised health professionals are intended users, alongside people at increased risk, patients and relatives.[19][2]Recommendations are normative guidance under the Norwegian Directorate of Health, but clinicians should use professional judgement for individual circumstances and document substantial departures from recommendations.[20]

• Offer risk assessment on request or when symptoms, markedly raised risk factors or family history indicate increased risk, rather than through routine population screening.[5]
• Assess age, sex, smoking, systolic blood pressure and total cholesterol using NORRISK 2, while considering treated hypertension, low high-density lipoprotein cholesterol, premature myocardial infarction in first-degree relatives and relevant comorbidities.[8][4][21]
• Confirm hypertension through standardised repeated office measurements and, where appropriate, home or 24-hour ambulatory monitoring to identify white-coat and masked hypertension.[22][23][24]
• Measure lipid profiles for cardiovascular risk assessment and follow-up, investigate possible secondary and inherited lipid disorders, and use low-density lipoprotein cholesterol to guide response and treatment targets.[25][26][27]
• Provide lifestyle support before or alongside medicines, including dietary counselling, smoking-cessation support with motivational and pharmacological options, physical-activity advice and access to cardiac rehabilitation or municipal Healthy Life Centres where relevant.[28][29][30][16][31]
• Use preventive medicines selectively: antihypertensives according to blood pressure and overall risk; statins according to risk, lipid levels and prevention setting; antiplatelet therapy only exceptionally in primary prevention but routinely for established atherosclerotic cardiovascular disease unless contraindicated.[32][33][34][35]
• Monitor treatment response, adverse effects, adherence and patient preferences through regular follow-up, usually reassessing lifestyle change after 3–12 months and undertaking at least annual medical review for people receiving medicines.[19][36]
• Use blood-pressure and lipid targets as clinical follow-up measures, including clinic blood pressure below 140/90 mmHg for most adults, a systolic target of 140–150 mmHg for people over 80, and lower low-density lipoprotein cholesterol targets for diabetes and established cardiovascular disease.[36][37]
• Involve pharmacists, home-care nurses and other municipal professionals in medication review for people with multiple conditions or extensive medicine use.[36][18]
• Prioritise people at highest risk when capacity is limited, as follow-up, risk assessment and monitoring require substantial primary-care resources.[38][39]

The guideline’s evidence base combines the earlier 2009 review, targeted searches for newer evidence, non-systematic PubMed searches, systematic searches on selected questions for older people, international cardiovascular guidelines and working-group expertise.[40]The Norwegian Directorate of Health led guideline development and maintenance, with a multidisciplinary working group that included primary and specialist clinicians, researchers, statisticians, patient representatives, a medicines regulator and health-authority staff; members submitted conflict-of-interest declarations assessed by the Directorate.[20][41]The available material does not specify a national implementation timetable, formal reporting cycle, surveillance system or comprehensive document-level performance framework beyond clinical targets, rehabilitation participation figures and selected measures of adherence and risk-factor control.[42][43][2]

Monitoring & Evaluation

The guideline’s monitoring approach is principally clinical and risk-based, supporting cardiovascular prevention through repeated assessment of risk factors, treatment response, adherence, adverse effects and patient preferences. It operates within Norway’s 2013–2017 non-communicable disease strategy, whose overarching objective was a 25% reduction in premature deaths from major non-communicable diseases by 2025.[1][2]

• Use NORRISK 2 to estimate 10-year cardiovascular risk and support age-specific intervention thresholds of 5%, 10% and 15%; threshold selection balances sensitivity, defined as correctly identifying people who later experience myocardial infarction or stroke, and specificity, defined as correctly identifying those who do not.[3][44][45]
• Reassess lifestyle measures and cardiovascular risk after 3–12 months where medicine treatment is being considered, then monitor treatment targets, adherence, symptoms and adverse effects through general-practice follow-up.[8][19][36]
• Monitor blood pressure using clinic, home or ambulatory measures where appropriate, with common targets below 140/90 mmHg in clinic, 135/85 mmHg at home or during daytime ambulatory monitoring, 130/80 mmHg over 24 hours and 120/70 mmHg at night; people over 80 have a systolic target below 150 mmHg.[36][37]
• Monitor lipid treatment through low-density lipoprotein cholesterol, lipid profiles and safety tests. Statin follow-up includes lipids and transaminases after initiation, annual diabetes-risk checks where relevant, and creatine kinase testing for new or worsening muscle symptoms.[46][47]
• Monitor antihypertensive treatment through blood-pressure control, renal function, electrolytes, adherence and adverse effects; older people require assessment for orthostatic hypotension, falls risk and continuing indication for each medicine.[48][49][18][50]
• Track rehabilitation participation as an implementation measure, as reported cardiac-rehabilitation figures showed 62% referral, 23% attendance and 5% programme completion.[42]
• Use the proportion of adults meeting minimum physical-activity recommendations as a population measure; a 2014–2015 survey found 32% met the recommendation.[51]

Evidence assessment is embedded throughout the guideline, drawing on randomised trials, meta-analyses, observational studies and international guidance, while explicitly noting weak or indirect evidence in several areas, including some lifestyle interventions, risk-assessment processes and care for older people.[52][53][54][40]The Norwegian Directorate of Health is responsible for developing, communicating and maintaining national professional guidance; substantial departures from recommendations should be documented and justifiable in complaints or supervisory proceedings.[2][20]The supplied material does not establish a comprehensive national reporting cycle, surveillance system, unified indicator set, audit process or named implementation-accountability mechanism beyond these clinical, governance and service-use measures.[2][20]

Costing & Financing

Economic considerations favour directing preventive resources towards people with substantial expected cardiovascular benefit, while recognising that assessment, monitoring, follow-up and counselling create demands on primary-care capacity.[55][39][38]The supplied material does not provide an overall guideline budget, financing plan, funding gap, resource-mobilisation target or quantified programme-level economic assumptions.[1][2][20]

• Recognise that lipid profiling requires sample collection, laboratory analysis and clinical assessment, while lipid-lowering medicines are generally characterised as low-cost.[27][56]
• Prioritise statin treatment where risk assessment indicates likely benefit, as medicine costs are described as low but risk assessment, monitoring and follow-up may generate substantial costs and use primary-care capacity.[39]
• Account for high medicine costs and reimbursement restrictions for proprotein convertase subtilisin/kexin type 9 inhibitors, including individual reimbursement applications in secondary prevention.[57][58]
• Recognise that smoking-cessation support requires staff time and medicine expenditure, with medicine costs reported as borne by patients; nevertheless, cessation support is characterised as highly cost-effective.[59]
• Allocate resources for hypertension assessment, initiation and follow-up, mainly in primary care. Medicine costs have fallen substantially, and guideline-based treatment is described as cost-saving or cost-effective, particularly for people at high risk.[60][61]
• Consider physical-activity and rehabilitation delivery costs: increasing activity generally requires limited resources, outpatient adapted rehabilitation has relatively small costs, whereas extensive rehabilitation stays entail costs.[62][63]
• Use low-cost secondary-prevention medicines where indicated. Acetylsalicylic acid is described as inexpensive and requiring little follow-up, while antiplatelet alternatives are also regarded as relatively inexpensive.[64][65]
• Recognise that tailored dietary counselling is time-consuming and requires repeated follow-up, although sustained dietary improvement is described as potentially delivering health benefits at almost no cost and reducing medicine needs.[66]

Patients may also bear costs through medicines, consultation payments, travel or time attending assessments and monitoring, while adverse effects can impose further personal burden.[67]Resource constraints should therefore inform prioritisation, particularly in primary care, without substituting for individual benefit-risk assessment and shared decision-making.[38][55]